Russian Journal of Infection and ImmunityRussian Journal of Infection and ImmunityИнфекция и иммунитет2220-76192313-7398SPb RAACI186410.15789/2220-7619-CBL-1864ORIGINAL ARTICLESОРИГИНАЛЬНЫЕ СТАТЬИResearch ArticleA correlation between LP-PLA2 and monocyte levels in atherosclerosis risk subjectsКорреляция уровней LP-PLA2 и моноцитов у людей с риском атеросклерозаhttps://orcid.org/0000-0003-2124-8673KumboyonoK.КумбойоноК.
Indonesia

School of Nursing, Faculty of Health Sciences

Школа сестринского дела, факультет наук о здоровье

publikasikoe@gmail.comhttps://orcid.org/0000-0002-1050-3571ChomsyIndah N.ЧомсиИ. Н.
Indonesia

Doctoral Program of Medical Science, Faculty of Medicine

докторская программа медицинских наук, медицинский факультет

indahncys@gmail.comVijayadasDineshВиджаядасД.
Indonesia

Medical Study Program, Faculty of Medicine

программа медицинского обучения, медицинский факультет

vidst@icloud.comhttps://orcid.org/0000-0001-6476-0541WihastutiTitin AВихастутиТитин Андри
Indonesia

School of Nursing, Faculty of Health Sciences

Школа сестринского дела, факультет наук о здоровье

titinwihastuti@gmail.comUniversity of BrawijayaУниверситет Бравиджая1511202230122022126113611421101202221032022Copyright ©; 2022, Kumboyono K., Chomsy I.N., Vijayadas D., Wihastuti T.A.Copyright ©; 2022, Кумбойоно К., Чомси И.Н., Виджаядас Д., Вихастути Т.А.2022Kumboyono K., Chomsy I.N., Vijayadas D., Wihastuti T.A.Кумбойоно К., Чомси И.Н., Виджаядас Д., Вихастути Т.А.https://creativecommons.org/licenses/by/4.0https://iimmun.ru/iimm/article/view/1864

Background. Cardiovascular disease (CVD) is the most significant cause of death worldwide. More than 17.9 million people died from CVD, of which 85% deceased due to heart disease. On the other hand, atherosclerosis is one of the most dominant CVD in most developing countries and developed countries. Lp-PLA2 is an enzyme produced by inflammatory cells and a pro-atherogenic protein in atherosclerosis. In the process, monocytes will produce Lp-PLA2 so that it may hydrolyse oxidized low density lipoprotein (oxLDL) into lysophosphatidylcholine (lysoPC) and oxidized fatty acids (oxFA), atherogenic proteins involved in atherogenesis. A chronic inflammatory process that occurs in atherosclerosis requires early detection to avoid CVD severity. The research aims to determine the correlation between Lp-PLA2 concentration and monocyte count as well as percentage in cohorts linked to risk of atherosclerosis. Materials and methods. This study was a descriptive correlational analysis of the population with conditions at risk of atherosclerosis. The total number of respondents sampled in this research was 86. We used the ELISA method to measure Lp-PLA2 concentration and the Hematology Analyzer method to measure monocyte count and percentage. Results. The relationship between monocyte and Lp-PLA2 level accounts for a probability value of 0.028. The correlation coefficient of 0.789 is categorized as very strong. Conclusion. Increase in the concentration of Lp-PLA2 correlates with monocyte count and percentage in a population with conditions at risk of atherosclerosis.

Актуальность. Сердечно-сосудистые заболевания (ССЗ) являются наиболее серьезной причиной смертности во всем мире. От сердечно-сосудистых заболеваний умерло более 17,9 млн человек, из них 85% — от болезней сердца. С другой стороны, атеросклероз является одним из наиболее распространенных ССЗ в большинстве развивающихся и развитых стран. Lp-PLA2 является ферментом, синтезируемым воспалительными клетками, и проатерогенным белком при атеросклерозе. При этом моноциты продуцируют Lp-PLA2 для гидролиза окисленного липопротеина низкой плотности (oxLDL) в лизофосфатидилхолин (lysoPC) и окисленные жирные кислоты (oxFA), атерогенные белки, участвующие в атерогенезе. Хронический воспалительный процесс, возникающий при атеросклерозе, требует раннего выявления во избежание утяжеления ССЗ. Исследование направлено на определение корреляции между концентрацией Lp-PLA2 и количеством моноцитов, а также процентом в группах лиц, связанных с риском атеросклероза. Материалы и методы. Настоящее исследование представляло собой описательный корреляционный анализ населения с состояниями, подверженными риску атеросклероза. Общее количество лиц, отобранных в этом исследовании, составило 86. Мы использовали метод ELISA для измерения концентрации Lp-PLA2 и метод гематологического анализатора для измерения количества и процентного содержания моноцитов. Результаты. Взаимосвязь между уровнем моноцитов и Lp-PLA2 составляет значение вероятности 0,028. Коэффициент корреляции 0,789 относится к категории очень сильных. Заключение. Увеличение концентрации Lp-PLA2 коррелирует с количеством и процентом моноцитов в популяции с состояниями риска атеросклероза.

atherosclerosisenzymeLp-PLA2inflammatory cellsmonocytes populationpro-atherogenic markerатеросклерозферментLp-PLA2клетки воспаленияпопуляция моноцитовпроатерогенный маркерAnzola L.K., Rivera J.N., Ramirez J.C., Signore A., Mut F. Molecular imaging of vulnerable coronary plaque with radiolabeled somatostatin receptors (SSTR). J. Clin. Med., 2021, vol. 10, no. 23: 5515. doi: 10.3390/jcm10235515Ashraf M.A., Nookala V. Biochemistry of platelet activating factor. In: StatPearlsTreasure Island (FL): StatPearls Publishing; 2021. URL: https://www.ncbi.nlm.nih.gov/books/NBK557392 (07.01.2022)Badimon L., Padró T., Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur. Heart J. Acute Cardiovasc. Care, 2012, vol. 1, no. 1, pp. 60–74. doi: 10.1177/2048872612441582Badimon L., Vilahur, G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J. Intern. Med., 2014, vol. 276, no. 6, pp. 618–632. doi: 10.1111/joim.12296Brilakis E., Khera A., McGuire D., See R., Banerjee S., Murphy S., de Lemos J. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis, 2008, vol. 199, no. 1, pp. 110–115.Cai A., Li G., Chen J., Li X., Li L., Zhou Y. Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population. BMC Cardiovasc. Disord., 2015, vol. 15, no. 14. doi: 10.1186/s12872-015-0001-9Cardiovascular and and all-cause mortality over a 23-year period among Chinese with newly diagnosed diabetes in the Da Qing IGT and diabetes study. Diabetes Care, 2015, vol. 38, no. 7, pp. 1365–1371. doi: 10.2337/dc14-2498Coleman J.F. Robbins and Cotran's Pathologic Basis of Disease. Am. J. Surg. Pathol., 2010, vol. 34, no. 1: 132. doi: 10.1097/PAS.0b013e3181bc5f0fColley K.J., Wolfert R.L., Cobble M.E. Lipoprotein associated phospholipase A2: Role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J., 2011, vol. 2, no. 1, pp. 27–38. doi: 10.1007/s13167-011-0063-4Da Silva I., Timm A. Damasceno N. Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (LP-PLA2 ) activity in adolescents: the healthy young cross-sectional study. Lipids Health Dis., 2013, vol. 12, no. 1: 19. doi: 10.1186/1476-511X-12-19Franekvá J., Kettner J., Kubíček Z., Jabor A. The importance of age and statin therapy in the interpretation of LP-PLA2 in ACS patients, and relation to CRP. Physiol. Res., 2015, vol. 64, pp. 229–236. doi: 10.33549/physiolres.932765Gencer S., Evans B.R., van der Vorst E., Döring Y., Weber C. Inflammatory chemokines in atherosclerosis. Cells, 2021, vol. 10, no. 2: 226. doi: 10.3390/cells10020226Hilgendorf I., Swirski F.K., Robbins C.S. Monocyte fate in atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2015, vol. 35, no. 2, pp. 272–279. doi: 10.1161/ATVBAHA.114.303565Jaipersad A.S., Lip G.Y.H., Silverman S., Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J. Am. Coll. Cardiol., 2014, vol. 63, no. 1, pp. 1–11. doi: 10.1016/j.jacc.2013.09.019Kim M., Yoo H., Kim M., Ahn H., Park J., Lee S., Lee J. Associations among oxidative stress, Lp-PLA 2 activity and arterial stiffness according to blood pressure status at a 3.5-year follow-up in subjects with prehypertension. Atherosclerosis, 2017, vol. 257, pp. 179–185. doi: 10.1016/j.atherosclerosis.2017.01.006Libby P., DiCarli M., Weissleder R. The vascular biology of atherosclerosis and imaging targets. J. Nucl. Med., 2010, vol. 51, suppl. 1, pp. 33S–37S. doi: 10.2967/jnumed.109.069633Lin P., Ji H.H., Li Y.J., Guo S.D. Macrophage plasticity and atherosclerosis therapy. Front. Mol. Biosci., 2021, vol. 8: 679797. doi: 10.3389/fmolb.2021.679797Lind L., Simon T., Johansson L., Kotti S., Hansen T., Machecourt J., Ninio E., Tedgui A., Danchin N., Ahlström H., Mallat Z. Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality. Eur. Heart. J., 2012, vol. 33, no. 23, pp. 2946–2954.Linton M.R.F., Yancey P.G., Davies S.S., Jerome W.G., Linton E.F., Song W.L., Doran A.C., Vickers K.C. The role of lipids and lipoproteins in atherosclerosis. 2019. In: Endotext. Eds.: Feingold K.R., Anawalt B., Boyce A., Chrousos G., de Herder W.W., Dhatariya K., Dungan K., Hershman J.M., Hofland J., Kalra S., Kaltsas G., Koch C., Kopp P., Korbonits M., Kovacs C.S., Kuohung W., Laferrère B., Levy M., McGee E.A., McLachlan R., Morley J.E., New M., Purnell J., Sahay R., Singer F., Sperling M.A., Stratakis C.A., Trence D.L., Wilson D.P. South Dartmouth (MA): MDText.com, Inc.; 2000. URL: https://www.ncbi.nlm.nih.gov/books/NBK343489 (07.01.2022)Maekawa Y., Anzai T., Yoshikawa T., Asakura Y., Takahashi T., Ishikawa S., Ogawa S. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction:a possible role for left ventricular remodeling. J. Am. Coll. Cardiol., 2002, vol. 39, no. 2, pp. 241–246. doi: 10.1016/S0735-1097(01)01721-1Moore K.J., Sheedy F.J., Fisher E.A. Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol., 2013, vol. 13, no. 10, pp. 709–721. doi: 10.1038/nri3520Rafieian-Kopaei M., Setorki M., Doudi M., Baradaran A., Nasri H. Atherosclerosis: process, indicators, risk factors and new hopes. Int. J. Prev. Med., 2014, vol. 5, no. 8, pp. 927–946.Rogacev K.S., Ulrich C., Blömer L., Hornof F., Oste K., Ziegelin, M., Heine G.H. Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur. Heart. J., 2010, vol. 31, no. 3, pp. 369–376. doi: 10.1093/eurheartj/ehp308Roved J., Westerdahl H., Hasselquist D. Sex differences in immune responses: hormonal effects, antagonistic selection, and evolutionary consequences. Horm. Behav., 2017, vol. 88, pp. 95–105. doi: 10.1016/j.yhbeh.2016.11.017Saougos V., Tambaki A., Kalogirou M., Kostapanos M., Gazi I., Wolfert R., Elisaf M., Tselepis A. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler. Thromb. Vasc. Biol., 2007, vol. 27, no. 10, pp. 2236–2243. doi: 10.1161/ATVBAHA.107.147280Sertić J., Lovrić J., Bozina T., Skorić B. and Reiner Z. Does LP-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease? Acta Med. Croatica, 2010, vol. 64, no. 4, pp. 237–245.Siddiqui M., Kennedy G., Carr F., Doney A., Pearson E., Morris A., Johnson T., McLaughlin M., Williams R. Palmer C. Lp-PLA2 activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study. Diabetologia, 2018, vol. 61, no. 6, pp. 1344–1353.Steen D.L., O’Donoghue M.L. LP-PLA2 Inhibitors for the reduction of cardiovascular events. Cardiol. Ther., 2013, vol. 2, no. 2, pp. 125–134. doi: 10.1007/s40119-013-0022-3Stone N.J., Robinson J.G., Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H., Goldberg A.C., Gordon D., Levy D., Lloyd-Jones D.M., McBride P., Schwartz J.S., Shero S.T., Smith S.C. Jr., Watson K., Wilson P.W. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol., 2014, vol. 63, no. 25, part B, pp. 2889–2934. doi: 10.1016/j.jacc.2013.11.002Tolani S., Pagler T.A., Murphy A.J., Bochem A.E., Abramowicz S., Welch C., Nagareddy P.R., Holleran S., Hovingh G.K., Kuivenhoven J.A., Tall A.R. Hypercholesterolemia and reduced HDL-C promote hematopoietic stem cell proliferation and monocytosis: studies in mice and FH children. Atherosclerosis, 2013, vol. 229, no. 1, pp. 79–85. doi: 10.1016/j.atherosclerosis.2013.03.031Wang J., Jin M., Chen Y., Yuan Y., Ruan Y., Lu G. Lp-PLA2, a potential protector of lung cancer patients complicated with pleural effusion from lung diseases, proves effective for the diagnosis and pathological classification of lung cancer. Transl. Oncol., 2021,vol. 14, no. 4: 101030. doi: 10.1016/j.tranon.2021.101030Wihastuti T.A., Saka P.N.B., Sargowo D., Heriansyah T. The effect of darapladib administration to inflammation marker in early development of atherosclerosis: in vivo study for dyslipidemia model. Eur. Heart. J., 2019, vol. 21 (suppl. F), p. F51.World Health Organization (WHO). Cardiovascular Diseases (CVDs). 2017. URL: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (07.01.2022)Zhang F., Guo J., Yang F., Zhou Y. Lp-PLA2 evaluates the severity of carotid artery stenosis and predicts the occurrence of cerebrovascular events in high stroke-risk populations. J. Clin. Lab. Anal., 2021, vol. 35, no. 3: e23691. doi: 10.1002/jcla.23691